Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB, Hearing Loss Independent Risk Factor for Parkinson
WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. I'm Marco Meglio. New topline data from the phase 3 ReThink-ALZ study (NCT04994483) showed that treatment with investigational simufilam (Cassava Sciences), a small …